COX-2 is associated with chemo- and radiation resistance and poor patient outcome in a number of tumor entities [29,30,31,32,33,34,35] encouraging us to investigate whether COX-2 is a potential target in PPGLs. This evidence concerns the gene PTGS2 and neoplasm.